Αρχική World News CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced... World News CLDN18.2-Specific CAR T-Cell Therapy Prolongs PFS in Patients with Previously Treated Advanced Gastric or Gastro-oesophageal Junction Cancer Από Ogkologos - 14 Αυγούστου, 2025 821 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CT041-ST-01 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR FDA Approves Pralsetinib for RET-Altered Thyroid Cancers 2 Δεκεμβρίου, 2020 Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer 28 Ιουνίου, 2018 EMA Recommends Granting a Conditional Marketing Authorisation for Ciltacabtagene Autoleucel 22 Απριλίου, 2022 Adjuvant Dabrafenib Plus Trametinib Associated with Better RFS and DMFS than... 9 Ιουλίου, 2024 Φόρτωση περισσοτέρων HOT NEWS Rescue Cat Alerts Mom to Breast Cancer by “Aggressively” Cuddling Her... Caregivers Empower the Next Generation of Cancer Care Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... EMA Recommends Extension of Therapeutic Indications for Axicabtagene Ciloleucel